Business
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"text","content":"2022 Total Collaboration and Product Revenue of $355.6 million, Crysvita® revenue of $279.4 million and Dojolvi® revenue of $55.6 million 2023 expected Total Revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million Year-end 2022 cash balance of $896.7 million and 2023 guidance for Net Cash used in Operations expected to be less than $400 million NOVATO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter and full year ended December 31, 2022 and reaffirmed its financial guidance for 2023. “In 2022, we continued to reach more patients around the world as we successfully commercialized multiple products to treat rare diseases,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “2023 will be a year of meaningful development progress for us as we focus on data generation from two of our key programs, UX143 in osteogenesis imperfecta and GTX-102 in Angelman syndrome, and the continued advancement of our late-stage gene therapy programs.” Fourth Quarter and Full Year 2022 Selected Financial Data Tables and Financial Results Revenues (dollars in thousands) (unaudited) Three Months Ended December 31, Year Ended December 31, 2022 2021 2022 2021 Crysvita Collaboration and Product Revenues: North America Collaboration$66,903 $50,211 $215,024 $171,198 ROW Product Sales 7,698 5,272 42,678 21,422 Crysvita in Ultragenyx Territories1 74,601 55,483 257,702 192,620 EU Royalty Revenue 6,058 4,741 21,692 18,195 Total Crysvita Revenue 80,659 60,224 279,394 210,815 Dojolvi 16,412 11,825 55,612 39,560 Mepsevii 4,798 3,111 20,637 16,035 Total Collaboration and Product Revenues 101,869 75,160 355,643 266,410 Daiichi Sankyo 1,479 8,229 7,686 84,996 Total Revenue$103,348 $83,389 $363,329 $351,406 Net RevenuesFor the fourth quarter of 2022, Ultragenyx reported $103.3 million in total revenue. Ultragenyx recognized $74.6 million in Crysvita (burosumab) revenue in the Ultragenyx territories1, which includes $66.9 million in collaboration revenue in the North American profit-share territory and ne...